Data / Form D filings / Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc.: Form D filings
Eikon Therapeutics, Inc., a biotechnology company in Hayward, CA, filed 4 Form D notices with the SEC between 2021 and 2025. The latest, on February 28, 2025, reports $350.7 million sold of a $400 million offering to 27 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3929 POINT EDEN WAY, Hayward, CA, 94545
- Phone
- (415) 865-2050
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1861123
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | New notice | $399,999,934 | $350,700,037 | $49,299,897 | 27 | Feb 14, 2025 | sec.gov |
| Jun 1, 2023 | New notice | $534,999,983 | $140,759,782 | $394,240,201 | 21 | May 18, 2023 | sec.gov |
| Jan 6, 2022 | New notice | $524,999,783 | $517,764,785 | $7,234,998 | 43 | Dec 3, 2021 | sec.gov |
| May 13, 2021 | New notice | $107,811,248 | $102,537,782 | $5,273,466 | 12 | May 4, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Robbie M. Huffines | Director | |
| Joshua M. Wolfe | Director | |
| Dror M. Berman | Director | |
| James M. Tananbaum | Director | |
| Leon M. Chen | Director | |
| Kenneth M. Frazier | Director | |
| Robin M. Washington | Director | |
| Roger M. Perlmutter | Executive Officer, Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Feb 24, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Eikon Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.